Pharmacogenetic aspects of eprosartan therapy and polymorphic markers of renin-angiotensin-aldosterone system genes in Uzbek patients with essential arterial hypertension
Abstract
Aim. To investigate antihypertensive and anti-remodeling effects of eprosartan in Uzbek patients with essential arterial hypertension (AH), taking into consideration renin-angiotensin-aldosterone system genetic polymorphism.
Material and methods. The study included 48 Uzbek men with Stage I-II AH. Left ventricular (LV) myocardial mass was assessed by echocardiography (EchoCG), LV diastolic function — by Doppler EchoCG. Genomic DNA was extracted from peripheral blood leukocytes according to standard protocol, using the Diatom TM DNA Prep 200 kit. AGT, ACE, AT1R, and CYP11B2 gene polymorphism was investigated by gene amplification and primer PCR method. Eprosartan monotherapy lasted for 12 weeks.
Results. Twelve-week eprosartan therapy was associated with a good antihypertensive effect, LV hypertrophy regression, and LV diastolic function improvement, regardless of ACE gene I/D polymorphism, AGT gene M235T polymorphism, AT1R gene A1166C polymorphism, or CYP11B2 gene C344T polymorphism.
Conclusion. Antihypertensive effectiveness of eprosartan was independent of AGT, ACE, AT1R, or CYP11B2 gene polymorphic markers. LV hypertrophy regression during eprosartan treatment was associated with DD genotype of ACE gene I/D polymorphism, TT genotype of AGT gene М235Т polymorphism, AA genotype of AT1R gene А1166С polymorphism, and CT genotype of CYP11B2 gene С344Т polymorphism.
About the Authors
D. R. Kurbanova
Republican Specialized Cardiology Centre
Uzbekistan
Uzbekistan
Tashkent
N. Z. Srozhidinova
Republican Specialized Cardiology Centre
Uzbekistan
Uzbekistan
Tashkent
N. B. Tursunova
Republican Specialized Cardiology Centre
Uzbekistan
Uzbekistan
Tashkent
M. R. Eliseeva
Republican Specialized Cardiology Centre
Uzbekistan
Uzbekistan
Tashkent
References
1. Минушкина Л.О., Затейшиков Д.А., Кудряшова О.Ю., и др. Дисфункция эндотелия: связь с полиморфизмом гена рецептора (тип 1) ангиотензина II у больных ишемической болезнью сердца. Кардиология. 2000; 1: 20—4.
2. 2007 Guidelines for the Management of Arterial Hypertension. Eur Heart J 2007; 28: 1462-536.
3. Cambian F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin converting enzyme in a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
4. Devereux RB, Reichek N. Echocardiography determination of left ventricular mass in man; anatomic validation of the method. Circulation 1977; 55: 613-8.
5. Kupari M, Hautanen A, Lankinen L, et al. Association between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998; 97: 569-75.
6. Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17(1): 8-13.
7. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihyperten¬sive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15(5): 389-93.
8. Kurland L, Melhus H, Karlsson J, et al; Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19(10): 1783-7.
9. Liljedahl U, Karisson J, Melhus H, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13: 7-17.
10. Malmqvist K, Kahan T, Edner M, et al. Regression of left ven¬tricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19(6): 1167-76.
11. Mazzolai L, Nessberger J, Anbert J, et al. Blood pressure independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998; 6: 1324-30.
12. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23; 1311-25.
13. Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445: 151-2.
14. Russ AP, Maez W, Ruzicka V, et al. Rapid detection of the hypertension associated Met235Agt; Thr allele of the human angiotensinogen gene. Hum Mol Genet 1993; 2: 609-10.
15. Teichholtz LE, Kruelen T, Herman MV, Gorlin R. Problems in echocardiographic volume determination. Am J Cardiol 1976; 37: 7-11.
16. Yusuf S, Reddy S, Ounpun S, Anand S. Global burden of car¬diovascular diseases. Part 1: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-53.
Review
For citations:
Kurbanova D.R., Srozhidinova N.Z., Tursunova N.B., Eliseeva M.R. Pharmacogenetic aspects of eprosartan therapy and polymorphic markers of renin-angiotensin-aldosterone system genes in Uzbek patients with essential arterial hypertension. Cardiovascular Therapy and Prevention. 2009;8(3):41-46. (In Russ.)
Views:
456
Email this article 
